Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fujisawa/Yamanouchi Merger Will Create "Astellas Pharma"; Deal On Track For 2005

This article was originally published in The Pink Sheet Daily

Executive Summary

Astellas is based on the Latin, Greek and English words for stars and is intended to sound like Japanese expression for "to shine on tomorrow." The companies will outline Astellas business strategies and financial targets by November.

You may also be interested in...



Fujisawa's Antifungal Mycamine Clears FDA

The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.

Fujisawa's Antifungal Mycamine Clears FDA

The product will be rolled out by the summer, with detailing by Fujisawa's existing immunology and hospital sales forces. Micafungin is approved for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation and treatment of esophageal candidiasis.

Yamanouchi Seeks Larger U.S. Presence Through Fujisawa Merger

The $7.8 bil. deal would ramp up the companies' sales efforts to primary care physicians. In the U.S., Fujisawa details only to the specialty care audience, while Yamanouchi relies on out-licensing agreements.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel